Marvel Biosciences Announces Closing of Second Tranche of Private Placement
Rhea-AI Summary
Marvel Biosciences (TSXV: MRVL) has closed the second tranche of its non-brokered private placement, issuing 150,000 Units at $0.125 per Unit for gross proceeds of $18,750. Each Unit consists of one Common Share and one Warrant. The company paid $1,312.50 in finder's fees and issued 10,500 finder's warrants, exercisable at $0.175 per share for two years. The total offering aims to raise up to $1.5 million through 12 million Units. The proceeds will fund drug formulation, toxicology studies, and working capital. The company also corrected its March 28 press release regarding finder's fees and announced the termination of a previously announced private placement from January 7, 2025.
Positive
- Secured additional funding of $18,750 through private placement
- Proceeds will support drug development activities including formulation and toxicology studies
- Successful closing of second tranche indicates continued investor interest
Negative
- Small tranche size of only $18,750 compared to total offering target of $1.5 million
- Termination of previously announced private placement from January 2025
- Additional share dilution through unit issuance and finder's warrants
News Market Reaction
On the day this news was published, MBCOF declined 17.97%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Calgary, Alberta--(Newsfile Corp. - May 2, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that, further to its press release of March 28, 2025 and subject to approval of the TSX Venture Exchange (the "TSXV"), it has closed the second tranche of its non-brokered private placement of up to 12,000,000 units (the "Units") at a price of
The second tranche closing of the Offering resulted in the issuance of 150,000 Units for gross proceeds of
The Company also wishes to announce that its press release of March 28, 2025 erroneously reported that finders' fees and finders' warrants were paid to Abinvest Corporation and Abingdon Capital Corp. The Company confirms that no finders' fees or finders' warrants were paid to either Abinvest Corporation or Abingdon Capital Corp. in relation to the Offering.
The Offering is being made to accredited investors or to such other qualified persons under such other prospectus exemptions as the Company may approve, provided however, that the Offering will not be made to persons or pursuant to securities laws exemptions that would require either the preparation or the filing of a prospectus, offering memorandum or similar document by the Company.
The Common Shares and the Warrants are subject to a hold period and resale restriction in Canada that expires four months plus one day from the issuance of the Units (the "Hold Period") and such other restrictions as imposed under applicable securities legislation.
The proceeds of the Offering will be used for drug formulation, toxicology studies and for general working capital purposes. The Offering is subject to acceptance by the TSX Venture Exchange.
There is no material fact or material change about the Company that has not been generally disclosed.
The Company also wishes to announce the termination of its non-brokered private placement of common shares, which was announced on January 7, 2025 that was made to purchasers pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions.
About Marvel Biosciences Corp.
Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary- based pre-clinical stage pharmaceutical development biotechnology company. The Company is developing MB-204, a novel fluorinated derivative of the approved anti-Parkinson's drug Istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer's Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.
Contact Information:
Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/250364
FAQ
How much did Marvel Biosciences (MRVL) raise in the second tranche of its private placement?
What is the total target amount for Marvel Biosciences' (MRVL) private placement offering?
How will Marvel Biosciences (MRVL) use the proceeds from the private placement?
What are the terms of the Units in Marvel Biosciences' (MRVL) private placement?
